Lindbrook Capital’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $908 | Hold |
4,610
| – | – | ﹤0.01% | 2489 |
|
|
2024
Q4 | $2.48K | Sell |
4,610
-237
| -5% | -$128 | ﹤0.01% | 2242 |
|
|
2024
Q3 | $4.61K | Buy |
4,847
+237
| +5% | +$225 | ﹤0.01% | 2044 |
|
|
2024
Q2 | $4.49K | Sell |
4,610
-2,135
| -32% | -$2.08K | ﹤0.01% | 2048 |
|
|
2024
Q1 | $10.7K | Buy |
6,745
+2,135
| +46% | +$3.37K | ﹤0.01% | 1537 |
|
|
2023
Q4 | $3.66K | Hold |
4,610
| – | – | ﹤0.01% | 2041 |
|
|
2023
Q3 | $3.6K | Hold |
4,610
| – | – | ﹤0.01% | 1916 |
|
|
2023
Q2 | $4.26K | Buy |
+4,610
| New | +$4.26K | ﹤0.01% | 1884 |
|
|
2022
Q4 | – | Sell |
-3,084
| Closed | -$3K | – | 2825 |
|
|
2022
Q3 | $3K | Buy |
3,084
+2,766
| +870% | +$2.69K | ﹤0.01% | 1825 |
|
|
2022
Q2 | $1K | Buy |
318
+139
| +78% | +$437 | ﹤0.01% | 2125 |
|
|
2022
Q1 | $0 | Sell |
179
-3,096
| -95% | – | ﹤0.01% | 2461 |
|
|
2021
Q4 | $12K | Sell |
3,275
-5,392
| -62% | -$19.8K | ﹤0.01% | 1187 |
|
|
2021
Q3 | $45K | Buy |
8,667
+2,057
| +31% | +$10.7K | 0.01% | 462 |
|
|
2021
Q2 | $28K | Buy |
6,610
+5,000
| +311% | +$21.2K | 0.01% | 657 |
|
|
2021
Q1 | $9K | Hold |
1,610
| – | – | ﹤0.01% | 1038 |
|
|
2020
Q4 | $9K | Hold |
1,610
| – | – | ﹤0.01% | 931 |
|
|
2020
Q3 | $13K | Sell |
1,610
-2,448
| -60% | -$19.8K | ﹤0.01% | 745 |
|
|
2020
Q2 | $41K | Buy |
4,058
+3,120
| +333% | +$31.5K | 0.01% | 409 |
|
|
2020
Q1 | $3K | Buy |
+938
| New | +$3K | ﹤0.01% | 1150 |
|